Arrhythmias & electrophysiologyCohort study

Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks

Eur Heart JPublished

  • Retrospective cohort study
  • Japanese nationwide administrative claims database
  • inverse probability of treatment weighting
  • 6-month landmark

Authors' conclusion

This observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient's CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.

Study context

Population
Patients who underwent catheter ablation (CA) for atrial fibrillation (AF), without AF recurrence, Japan, April 2014–March 202171% continued oral anticoagulant (OAC)
Participants
231,374 patients
Exposure
Continued OAC vs no continued OAC 6 months after AF catheter ablation
Outcome
Thromboembolism and major bleeding, by CHADS2 score
Follow-up
After a landmark period of 6 months

Main finding

As reported in the abstract

Thromboembolism, by CHADS2 score
Continued OAC vs No continued OACHazard ratio (95% CI)P value
CHADS2 ≤1
0.86(0.74–1.01)
P = 0.06
CHADS2 ≥3
0.61(0.46–0.82)
P = 0.001
Thromboembolism, all patients
2451 (0.55 per 100 person-years)

Observational data: associations, not effects.

Further findings

OAC continuation by CHADS2 score · 6 months

OAC continuation rate higher in high than in low CHADS2 score group

Safety

OutcomeHR (95% CI)P value
Major bleeding, by CHADS2 score — Continued OAC vs No continued OAC · CHADS2 ≤1 · inverse probability of treatment weighting1.51 (1.27–1.80)P < 0.001
Major bleeding, by CHADS2 score — Continued OAC vs No continued OAC · CHADS2 ≥3 · inverse probability of treatment weighting1.05 (0.71–1.56)P = 0.81
Major bleeding, by CHADS2 score — Major bleeding, all patients
2367 (0.53 per 100 person-years)

Original publication

Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks. Eur Heart J. Published 20 December 2023. doi:10.1093/eurheartj/ehad798

Summarised from the published abstract; every number is checked against it